The replacement of the MBX hormone strikes the objective in the mid-term study

Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54.

A medication once a week of MBX BioSciences has achieved the main objective of a mid-term clinical trial for patients with chronic hypoparathyroidism, a type of hormonal disorder. However, the results reported on Monday were less impressive compared to the advantages of approved treatment.

In the 12 -week study, the MBX medication, called canvuparatide, posted a response rate of 63% compared to a placebo response of 31%. The effect of treatment was statistically significant but narrower than the expected, partly due to a high placebo response rate.

The result can let investors call into question the potential benefits of canvuparatide compared to Yorvipath, a medication competitor of Ascendis Pharma approved last year.